Viatris Inc. VTRS
Viatris Inc. (Nasdaq: VTRS) is a specialty pharmaceutical company. Its next catalyst on record is MR-141 (presbyopia): FDA action on supplemental NDA (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: MR-141 (presbyopia) — FDA action on supplemental NDA (H2 2026). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Low-dose estrogen weekly contraceptive patch | contraception | small molecule | Phase 3 |
| MR-141 (phentolamine ophthalmic solution 0.75%) | presbyopia | small molecule | Phase 3 |
| MR-142 (phentolamine ophthalmic solution 0.75%) | night driving impairment in keratorefractive patients | small molecule | Phase 3 |
| MR-107A-02 (fast-absorbing meloxicam) | moderate-to-severe acute pain | small molecule | Phase 3 |
| selatogrel | acute myocardial infarction (cardiovascular) | small molecule | Phase 3 |
| cenerimod | systemic lupus erythematosus | small molecule | Phase 3 |
Recent results and decisions
- Oct 8, 2026n/a Viatris enters definitive agreement to acquire Pacira BioSciences for $36.50 per share in cash, or $1.65 billion total equity value.
Viatris Inc. ... and Pacira BioSciences, Inc. ... announced that they have entered into a definitive agreement under which Viatris has agreed to acquire all of the outstanding shares of common stock of Pacira for $36.50 per share in cash, representing an aggregate equity value of $1.65 billion.
Filing - Oct 8, 2026n/a The Viatris acquisition of Pacira BioSciences is anticipated to close by the end of 2026.
Deal Anticipated to Close By the End of 2026 and to Be Immediately Accretive to Viatris' Financial Guidance Metrics
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.